New Delhi, April 27 -- Indian drug companies are increasingly looking overseas for growth, with acquisitions picking up and set to rise further as they seek to move beyond their reliance on generics and build stronger, more diverse businesses.

This trend comes amid global challenges witnessed over the past two years, including US tariff threats, price erosion in the generics market and a major shift by pharma companies towards biologics. These factors are collectively pushing Indian firms to explore new growth opportunities.

In a major hurdle for pharma firms, US President Donald Trump issued an executive order on 2 April, which imposes 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to...